If you’re already depressed, you may need help to make good decisions

In a rather less that surprising finding, a new paper in the Journal of Clinical Oncology reports that men with existing depressive disorders at the time of diagnosis with prostate cancer “are less likely to undergo definitive treatment and experience worse overall survival.” … READ MORE …

USPSTF on PSA screening … a current update …

The U.S. Preventive Services Task Force (USPSTF) has just issued its “Guide to Clinical Preventive Services” for 2014. The publication (which is available on line) includes summary information about screening for prostate cancer. … READ MORE …

Why would prostate cancer be less likely in HIV-positive men?

A new article has explored further previously reported observations that prostate cancer appears to occur with lower incidence in men already diagnosed as positive for human immunodeficiency virus (HIV) than in their HIV-negative, “normal” peers. … READ MORE …

Declining use of the DRE at a large VA medical center: is this a national trend?

Once upon a time (not so very long ago) the digital rectal examination or DRE was the only non-invasive test that a physician could use to assess whether a patient was at risk for localized prostate cancer and/or other prostate problems. Alas, the use of this test appears to be falling out of favor, which is probably not a good thing. … READ MORE …

Can biomarkers in semen accurately detect prostate cancer risk?

According to a research letter accepted for publication in the journal Endocrine-Related Cancer, a group of Australian researchers are suggesting that prostate cancer-specific biomarkers may be identifiable in male semen. … READ MORE …

MRI/TRUS fusion-guided biopsy in a community-like urology practice

A new study just reported in the Journal of Urology provides information on the application of MRI/TRUS fusion-guided prostate biopsy to diagnose prostate cancer in a community-like urology practice (as opposed to a major prostate cancer research center). … READ MORE …

A “proteomic-based” test for prostate cancer prognostic risk

Yet another new test will soon be available that claims to be able to differentiate with relative accuracy between clinically significant and clinically insignificant types of prostate cancer (again based on actual prostate cancer tissue from a biopsy sample or a surgical specimen). … READ MORE …

Liu and Zoey “are Ferraris” who massively outperform PSA testing

A report on the Medscape Oncology site on Tuesday discussed prostate cancer detection data presented at the annual meeting of the American Urological Association (AUA) by a group of Italian researchers — with the help of two highly trained German Shepherds. … READ MORE …

MRI- and MRI/TRUS fusion-guided biopsy: an up-to-date review

The first issue of the new journal Urology Practice includes a very nice review of the use of MRI imaging in the evaluation, diagnosis, and biopsy of men with prostate cancer. … READ MORE …

How to mislead the public: a case study in apparent naivety

An article in today’s Daily Telegraph in the UK starts with the misleading statement that, “Up to half of men diagnosed with prostate cancer are being given ‘false hope’ by tests that are underestimating the severity of their disease, according to the authors of a new study.” … READ MORE …

Circumcision and risk for prostate cancer: an unresolved debate

For more than 70 years there has been an ongoing if sporadic debate about whether circumcision (in infancy or later in life) has any impact on risk for prostate cancer … or not. … READ MORE …

Another potential genomic test for prostate cancer aggression

In a presentation given last Saturday at the annual meeting of the European Society for Radiotherapy and Oncology (ESTRO) in Vienna, a Canadian research team introduced yet another potential test that may be helpful in differentiating between patients at relatively high or low risk for metastasis, based on biopsy tissue. … READ MORE …

Gleason score and metastatic prostate cancer; risk for 4-year mortality

It is difficult to accurately interpret a set of data just published that was designed to assess the relationship between 4-year survival and Gleason score at diagnosis in men initially diagnosed with metastatic prostate cancer. … READ MORE …

OPKO launches 4Kscore Test™ for risk of prostate cancer; data still to come

According to a media release on the OPKO corporate web site, the company is now starting to carry out its previously discussed 4Kscore test for urologists and their patients here in the USA through its CLIA-accredited laboratory in Nashville, Tennessee. … READ MORE …

Just how good is multiparametric, 3-T MRI at finding, staging localized disease?

It is clear that modern magnetic resonance imaging is getting closer to being able to make a major difference to the way that we diagnose (and potentially manage) localized prostate cancer … always assuming we can afford the costs involved (at least here in the USA). … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,119 other followers